- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05661084
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia (ACDCStim)
Multifocal Transcranial Current Stimulation for Cognitive and Motor Dysfunction in Dementia
Study Overview
Status
Intervention / Treatment
- Device: Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)
- Device: Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)
- Device: Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)
- Device: Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: HomeStim Study
- Phone Number: 617-971-5416
- Email: homestim@hsl.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02131
- Recruiting
- Hinda and Arthur Marcus Institute for Aging Research
-
Principal Investigator:
- Brad Manor, PhD
-
Contact:
- Alvaro Pascual-Leone, MD; PhD
-
Contact:
- Maggie Syme, PhD
- Phone Number: 617-971-5338
- Email: maggiesyme@hsl.harvard.edu
-
Sub-Investigator:
- Davide Cappon, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants (Ps)
- willing and capable to give informed consent for the participation in the study after it has been thoroughly explained
- able and willing to comply with all study requirements
- an informed consent form was signed
- able to read, write, and communicate in English
- able to identify an eligible administrator to participate with them in the study
Caregiver/Administrators (As)
- at least 21 years of age
- able to read, write, and communicate in English
- self-reported computer proficiency and willingness to learn how to use tES as defined by "yes" answers to the questions "Do you feel comfortable using a computer?" and "Are you willing to be the primary caregiver for a participant and learn how to administer tES?"
- stated availability during weekdays throughout the study period to administer tES to the Ps
Exclusion Criteria:
Participants (Ps)
- major psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis
- blindness or other disabilities that prevent task performance
- contraindications to tES, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, etc.)
- the presence of any active dermatological condition, such as eczema, on the scalp a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen
- an inability to understand study procedures following review of the Informed Consent form
- Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator
Caregiver/Administrators (As)
- mild cognitive impairment defined by a MoCA score ≤26 during the in-person screen
- insufficient understanding of study procedures following review of the Informed Consent form
- Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.
- poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tES
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tACS(AG) + tDCS(PFC) combo active
Participants (Ps) will undergo 20min of daily home-based tACS active + tDCS active intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
|
Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
Other Names:
|
Active Comparator: tACS(AG) active + tDCS(PFC) sham
Participants (Ps) will undergo 20min of daily home-based tACS active + tDCS sham intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
|
Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator.
Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.
Other Names:
|
Active Comparator: tACS(AG) sham + tDCS(PFC) active
Participants (Ps) will undergo 20min of daily home-based tACS sham + tDCS active intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
|
Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator.
Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.
Other Names:
|
Sham Comparator: tACS(AG) sham + tDCS(PFC) sham
Participants (Ps) will undergo 20min of daily home-based tACS sham + tDCS sham intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).
|
A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.
It will physically mimic active stimulation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Rey Auditory Verbal Learning Test (RAVLT) Total Recall
Time Frame: baseline, immediate post-intervention, 3 month follow up , 6 month follow up
|
This test is designed to evaluate verbal memory in those 16 years of age and older.
It can be used to evaluate the nature and severity of memory dysfunction and to track changes in memory function over time.
Total recall is measured by the total number of words out of 15 the participant is able to recall.
Scores range from 0 to 15.
|
baseline, immediate post-intervention, 3 month follow up , 6 month follow up
|
Change in Dual Task Cost to Gait
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
This measure is captured by Mobility Lab™ (APDM Inc) software while the participant is walking with sensors at a) normal speed (speed for single task) and b) walking while counting backwards by 3's or 1's (speed dual task).
The formula for cost of the dual task to gait is: (speedsingletask-speeddualtask)/speedsingletask)*100).
Range for dual task cost is as follows: High Risk for falls > 0.2, Moderate Risk for falls <= 0.2, Low Risk < 0.1.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Functional Activity Questionnaire
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
This is a 10-item scale to measure functional status via independent activities of daily living. Each item is a functional activity, and the caregiver/informant rates the participant's ability using the following scoring system:
The scores are summed (range 0-30). Cut-point of 9 (dependent in 3 or more activities) is recommended to indicate impaired function and possible cognitive impairment. This test will be used to track functional status over the course of the intervention and follow-up. |
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Change in Montreal Cognitive Assessment (MoCA) total score, memory and executive subscores
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
The Montreal Cognitive Assessment (MoCA) is designed as a rapid screening instrument for mild cognitive dysfunction.
It assesses different cognitive domains.
The total possible score is 30 points; a score of 26 or above is considered normal.
Severity of impairment can be determined with the following scores: 18-25 = mild cognitive impairment, 10-17= moderate cognitive impairment, and less than 10= severe cognitive impairment.
The maximum total score is 30 and the minimum total score is 0 points.
The memory and executive subscales are each on a range of 0 to 5 points.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Average E-field normal component (En) for left angular gyrus and prefrontal cortex
Time Frame: immediate post-intervention
|
From magnetic resonance imaging, an E-field normal component value will be computer for each brain voxel.
From those measurements an average En value will be computed in the anatomically-defined left AG (i.e., Brodmann areas 39/40), and separately the left PFC (i.e., Brodmann areas 39/40).
This outcome of average En will provide information on the amount of current each participant receives during the intervention in the targeted areas.
|
immediate post-intervention
|
Change in Adjusted Trail Making Test performance
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
The Trail Making Test (TMT) is a test of visual attention and task switching, which consists of two parts (A & B).
It is scored by timing how long it takes to complete each part of the test, separately.
The maximum time allowed for part A or part B is 300 seconds.
Age and education adjusted norms are available to determine standard scores.
The Adjusted performance is calculated by subtracting the time it takes to complete part A (in seconds) from the time it takes (in seconds) to complete part B. This is a measure of executive functioning and also has age and education adjusted norms.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Change in Stroop test response latency
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
The Stroop test assess the participant's ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute.
The outcome of response latencies, specifically, measures the average reaction time (in milliseconds) of the participant to a) the congruent trials (colors match words) and b) the incongruent trials (colors do not match words).
The average difference between congruent and incongruent response latencies will be examined.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Change in Gait speed
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
The speed of the participants gait during both a) normal walking and b) walking while counting backwards.
The speed is measured by the software, Mobility Lab, which is gathered via sensor.
Average gait speed varies by age and education.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Change in Stride time variability
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
This is measured by the software, Mobility Lab, which is gathered via sensor as the participant is walking.
The average stride time varies by age and education and is the coefficient of variation of stride times during a normal walk on a straight path.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Change in Short Physical Performance Battery total score
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
This is an assessment of lower extremity function, and combines results of gait speed, chair stand and balance tests.
The range of scores is from 0 to 12, with higher scores indicating better lower extremity functioning.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Change in 12-item Short Form Health Survey (SF-12)
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
The Short Form - 12 is a measure of health-related quality of life.
There are 12 items with responses either from 1 to 3 or 1 to 5 on a Likert-type scale.
Standardized scores are calculated for a physical component summary (PCS) and a mental component summary (PCS), with an average of 50 and a standard deviation of 10 and higher scores with better functioning.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Change in Average daily step count
Time Frame: baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
An average daily step count will be computed from data collected through an activity monitor over a 7-day period.
The average of the 7 days will be computed for an average daily step count.
|
baseline, immediate post-intervention, 3 month follow up, 6 month follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alvaro Pascual-Leone, MD; PhD, Hebrew SeniorLife
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00059707
- 1R01AG076708 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)
-
Tianjin Anding HospitalCompleted
-
Centre Hospitalier St AnneNot yet recruiting
-
Manhattan Psychiatric CenterCompletedSchizophrenia | Auditory HallucinationUnited States
-
D'Or Institute for Research and EducationCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompleted
-
ElsanRecruitingCancer Pain | Refractory PainFrance
-
VA Office of Research and DevelopmentRecruitingSuicide | ImpulsivityUnited States
-
VA Office of Research and DevelopmentRecruitingObesityUnited States
-
University Hospital TuebingenNIRX Medizintechnik GmbH, Gustav-Meyer Allee 25, 13355 Berlin; Hetzler Stiftung...RecruitingTobacco Use DisorderGermany
-
Minneapolis Veterans Affairs Medical CenterRecruitingAlzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Hebrew SeniorLifeNational Institute on Aging (NIA)Not yet recruitingFall | Mobility Limitation | Gait, UnsteadyUnited States